| Literature DB >> 32038731 |
Mina Jamalvandi1, Hossein Khanahmad2, Shiva Irani1, Sayad Bastaminezhad3.
Abstract
Asthma as a chronic inflammatory disorder is associated with many cytokines like interleukin-5 (IL-5) which plays essential role in eosinophil differentiation and maturation. Accordingly, blockage of IL-5 using mepalizumab has been considered as a promising therapeutic approach for asthma. Despite the monocolonal antibody advantages, some restrictions provided an acceptable background for alternative agents like aptamers which could replace with antibodies. In the current study, aptamer isolation against IL-5 molecule was intended, according to the valuable benefits of aptamers over antibodies. HEK-293T/IL-5 cell was constructed to select aptamer using cell-systematic evolution of ligands by exponential enrichment (SELEX) method. Integration of the IL-5 fragment to genome of the HEK-293T was verified by polymerase chain reaction on the genomic DNA of the transfected cells. Moreover, IL-5 protein expression on the cell surface was confirmed using flow cytometry analysis. Then, cell SELEX was carried out in 12 rounds and isolated aptamers were evaluated by flow cytometry analysis. The selected clones were then sequenced and assessed for any possible secondary structure. The results of this study led to the selection of 19 different single-stranded DNA clones after 12 rounds of selection which were clustered to five groups based on common structural motifs. In conclusion, the findings revealed the isolation of IL-5-specific single-stranded DNA aptamers, which can further be substituted with mepolizumab. Copyright:Entities:
Keywords: Aptamer; Asthma; Cell-SELEX; HEK-293T; Interleukin-5
Year: 2019 PMID: 32038731 PMCID: PMC6937751 DOI: 10.4103/1735-5362.272560
Source DB: PubMed Journal: Res Pharm Sci ISSN: 1735-5362
DNA aptamer selected sequences against interleukine 5.
| Clone | Family | Sequence |
|---|---|---|
| 3E | 1 | ATACCAGCTTATTCAATTCGAGGAACGAGAATTGCCAACTGGATGCCGACAGCTTGGACCTATATTTGAAAGATAGTAAGTGCAATCACAGTGT |
| 11E | 1 | ATACCAGCTTATTCAATTCGAGGAACGAGAATTGCCAACTGGACGCCGACAGCTTGGAACTATATTCGAAAGATAGTAAGTGCAATCACAGTGT |
| 36E | 1 | ATACCAGCTTATTCAATTCGAGGAACGAGAATTGCCAACTGGAGGCCGACAGCTTGGACGTACATTTGAAAGATAGTAAGTGCAATCACAGTGT |
| 53E | 1 | ATACCAGCTTATTCAATTCGAGGAACGAGAATTGCCAACTGGATCCCGACAGCTTGGAGGTATATTTGAAAGATAGTAAGTGCAATCACAGTGT |
| 9E | 2 | ATACCAGCTTATTCAATTCTATCTCAAGCCACATGATGGGATGCGTCTGTGTAGTGAATACGGAATGCCCACACTGTGATTGCACTTACTATCT |
| 19E | 2 | ATACCAGCTTATTCAATTCTATCCCAAGCGACATGATGGGATGCGTGTGTGTAGTGATTACGGAATGCCCACACTGTGATTGCACTTACTATCT |
| 42E | 2 | ATACCAGCTTATTCAATTCTATCTCAAGCCACATGATGCGATGTGTCTTTGTAGTGAATACGCCATGCCCACACTGTGATTGCACTTACTATCT |
| 12E | 3 | ATACCAGCTTATTCAATTCGCGTGAGTAACATAAACTGTCGAGGCAACGGGAATGTCCCGTAGCTGTTGTAGATAGTAAGTGCAATCACAGTGT |
| 21E | 3 | ATACCAGCTTATTCAATTCGCGTGAGTAACATTCACTGTCGAGGCAACGGGAATGTGTCGTAGCTGTGGTAGATAGTAAGTGCAATCACAGTGT |
| 25E | 3 | ATACCAGCTTATTCAATTCGCGTGAGGTACATTAACTGTCGAGCCAACGGGAATGTGTCGTAGCTGTCGTAGATAGTAAGTGCAATCACAGTGT |
| 29E | 3 | ATACCAGCTTATTCAATTCGCGTGAGTTCCATACACTGTCGACGCAACGGGAATGTCTCGTAGCTGTAGTAGATAGTAAGTGCAATCACAGTGT |
| 33E | 3 | ATACCAGCTTATTCAATTCGCGTGAGTAACATtAACTGaCGAGGCAACGGGAATGTCCCGTAGCTaTaGTAGATAGTAAGTGCAATCACAGTGT |
| 14E | 4 | ATACCAGCTTATTCAATTGGGGTAAGGGGACCCGATTGCAATGCTCGTGCAGGGGGTTGGCCTGATCTAGAGATAGTAAGTGCAATCACAGTGT |
| 18E | 4 | ATACCAGCTTATTCAATTGGGGTAAGGCCACCGGATTGCAATGCTTGTGCAGGGGGTTGGCCTGATCTAGAGATAGTAAGTGCAATCACAGTGT |
| 50E | 4 | ATACCAGCTTATTCAATTGGAGTAAGGGAAGGCGATTTCAATGCTCGTGCAGGGGGTTGGCCTGATCTAGAGATAGTAAGTGCAATCACAGTGT |
| 8E | 5 | ATACCAGCTTATTCAATTCTATCTCTCTTAACACCTTGTTGCCCAAGTCGGAAATAAACGTACCAAGTCCACACTGTGATTGCACTTACTATCT |
| 15E | 5 | ATACCAGCTTATTCAATTCTATCTCTCTTTACACCTTGTTGCACAAGTCGGAAATAAACGTACCAATTCCACACTGTGATTGCACTTACTATCT |
| 13E | - | ATACCAGCTTATTCAATTCTATCTTTCAGGGGATTGGTGTGGATCTGTCGTTGTAGTTCCCGTTCAATTACACTGTGATTGCACTTACTATCT |
| 47E | - | ATACCAGCTTATTCAATTCTATCTTTCAGTTGATTGGTGTGGATCTGCCGTTGTAGTTCGCGTTCATATACACTGTGATTGCACTTACTATCT |
Fig. 1Verification of pCDNA/IL-5 insertion. (A) Genomic DNA amplification. Agarose gel electrophoresis results illustrated the insertion of IL-5 gene into the genome of transfected cells; Lane 1, untransfected cells; lane 2, DNA marker (1 kb Fermentas); and lane 3, amplified fragment of transfected cells (618 bp). (B and C) Expression level of IL-5 protein on HEK-293T cell surface. Flow cytometric analysis shows 76% expression of IL-5 protein on (C) the transfected cells compared to (B) the un-transfected cells.
Fig. 2Cell-SELEX progression monitoring. Cell samples were prepared for the flow cytometry aptamer binding assay with 1 × 105 cells and 750 nM of DNA aptamers. FITC fluorescence emission of the live cell population is presented for the: (A) initial library, (B) forth, (C) eighth, and (D) twelfth rounds of SELEX which have the mean fluorescent intensity more than M1 (initial library), 11.47%, 51.68%, and 73.70%, respectively. FITC, fluorescein isothiocyanate; SELEX, systematic evolution of ligands by exponential enrichment.
Fig. 3Phylogenetic tree, alignment and clustering. (A) ClustalX phylogenetic tree analysis of the 92 bp DNA sequences from 19 different clones. (B) DNA sequence alignment. ClustalX alignment of the 92 bp sequences for the DNA sequences in the 11th SELEX round pool illustrated five families of sequences emerge that have 90% sequence identity within each family. Common nucleotides in all families are denoted with an asterisk. SELEX, systematic evolution of ligands by exponential enrichment.
Fig. 4Secondary structure predictions. Predicted secondary structures for the five families of aptamer candidates that were chosen from the 11th round of SELEX. (A) to (E) are representatives of families 1 to 5, respectively with lowest potential energy structures in each family to bind interleukin-5 expressing cells. Secondary structures were predicted by DNAMAN software. SELEX, systematic evolution of ligands by exponential enrichment